A study of the effects of deregulation on radio commercialization: A direct methodology for data collection

Nine years after deregulation became policy in commercial radio broadcasting, a study of the effects of the provision in the deregulatory position the Federal Communications Ccmnission took in 1981 which eliminated any restrictions on the amount of commercial time a station could air in a given hour was conducted on 13 radio stations in five Nebraska markets. Because the logging requirements to which broadcasters had to adhere were eliminated with deregulation, the data in this survey was collected by tape recording, then analyzing by 195 hours of actual radio broadcasts. Of the 13 stations surveyed during the peak hours of the day (drive times), the peak days of the week (Wednesday through Friday) and at different times of the year, two stations, both in small, non-ccmpetitive markets were found to have exceeded the previous limit of 18 minutes per hour. The research found that the foundation of the marketplace model, upon which deregulation is based, is potentially flawed when projected on those markets which are not served by multiple radio properties. Further, the research advocates the direct methodology of monitoring not only the effects of deregulation on overcommercialization, but on any monitoring research conducted on broadcast content because the researcher has much more control over the data collection process. Finally, the research is meant to stimulate more study of the effects of deregulation, particularly on the pervasive medium of radio

Insider trading and accounting reform: The Comstock case

This paper examines the hypothesis that major episodes of insider trading and business fraud promote accounting reforms. Dur-ing the 1860s and 1870s, the markets for Comstock mining shares reeled from one scandal after another. Eventually these scandals emerged as a leading political issue in California. The frauds contributed significantly to the passage of accounting and financial reporting reforms in 1880. The Comstock episode has implications for modern day instances of insider trading

Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: A randomized non-inferiority study

Background: Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25 μg has been shown to improve lung function and health status, and reduce exacerbations, versus budesonide/formoterol in patients with chronic obstructive pulmonary disease (COPD). We evaluated the non-inferiority of single-inhaler FF/UMEC/VI versus FF/VI + UMEC using two inhalers. Methods: Eligible patients with COPD (aged ≥40 years; ≥1 moderate/severe exacerbation in the 12 months before screening) were randomized (1:1; stratified by the number of long-acting bronchodilators [0, 1 or 2] per day during run-in) to receive 24-week FF/UMEC/VI 100/62.5/25 μg and placebo or FF/VI 100/25 μg + UMEC 62.5 μg; all treatments/placebo were delivered using the ELLIPTA inhaler once-daily in the morning. Primary endpoint: change from baseline in trough forced expiratory volume in 1 s (FEV1) at Week 24. The non-inferiority margin for the lower 95% confidence limit was set at − 50 mL. Results: A total of 1055 patients (844 [80%] of whom were enrolled on combination maintenance therapy) were randomized to receive FF/UMEC/VI (n = 527) or FF/VI + UMEC (n = 528). Mean change from baseline in trough FEV1 at Week 24 was 113 mL (95% CI 91, 135) for FF/UMEC/VI and 95 mL (95% CI 72, 117) for FF/VI + UMEC; the between-treatment difference of 18 mL (95% CI -13, 50) confirmed FF/UMEC/VI’s was considered non-inferior to FF/ VI + UMEC. At Week 24, the proportion of responders based on St George’s Respiratory Questionnaire Total score was 50% (FF/UMEC/VI) and 51% (FF/VI + UMEC); the proportion of responders based on the Transitional Dyspnea Index focal score was similar (56% both groups). A similar proportion of patients experienced a moderate/severe exacerbation in the FF/UMEC/VI (24%) and FF/VI + UMEC (27%) groups; the hazard ratio for time to first moderate/ severe exacerbation with FF/UMEC/VI versus FF/VI + UMEC was 0.87 (95% CI 0.68, 1.12). The incidence of adverse events was comparable in both groups (48%); the incidence of serious adverse events was 10% (FF/UMEC/VI) and 11% (FF/VI + UMEC). Conclusions: Single-inhaler triple therapy (FF/UMEC/VI) is non-inferior to two inhalers (FF/VI + UMEC) on trough FEV1 change from baseline at 24 weeks. Results were similar on all other measures of efficacy, health-related quality of life, and safety. Trial registration: GSK study CTT200812; ClinicalTrials.gov NCT02729051 (submitted 31 March 2016)

PANIC: A Near-infrared Camera for the Magellan Telescopes

PANIC (Persson's Auxiliary Nasmyth Infrared Camera) is a near-infrared camera designed to operate at any one of the f/11 folded ports of the 6.5m Magellan telescopes at Las Campanas Observatory, Chile. The instrument is built around a simple, all-refractive design that reimages the Magellan focal plane to a plate scale of 0.125'' pixel^{-1} onto a Rockwell 1024x1024 HgCdTe detector. The design goals for PANIC included excellent image quality to sample the superb seeing measured with the Magellan telescopes, high throughput, a relatively short construction time, and low cost. PANIC has now been in regular operation for over one year and has proved to be highly reliable and produce excellent images. The best recorded image quality has been ~0.2'' FWHM.Comment: 8 pages, 5 figures. To appear in "Astronomical Telescopes and Instrumentation," Proc SPIE (Glasgow), June 2004. Version with higher resolution figures is available at http://cfa-www.harvard.edu/~pmartini/professional/publications/panic.pd